P Shot New York City: The Evidence-First Guide for 2026

Any man in New York City who begins researching the P-Shot quickly runs into a wall of bold claims and almost no clinical citations. Marketing pages promise transformation but rarely explain what the science actually supports, who genuinely benefits, or where the honest limits sit. This guide takes a different approach.

The framework here is simple and consequential: PRP (the P-Shot) addresses erectile function and tissue regeneration, while hyaluronic acid (HA) filler addresses measurable aesthetic girth enhancement. These are distinct tools for distinct goals. Conflating them, as most competitor pages do, leaves men making decisions on incomplete information.

This article is written for the high-achieving professional who wants data before making a decision. It covers what the evidence shows, what it does not show, who is a real candidate, how NYC pricing works, and when filler becomes the logical complement. All of it reflects the most recent meta-analyses and randomized controlled trial (RCT) data available in 2026.

What Is the P-Shot? A Clinically Accurate Overview

The P-Shot (Priapus Shot®) is a non-surgical, in-office procedure that uses platelet-rich plasma (PRP), or the advanced variant known as Platelet-Rich Fibrin Matrix (PRFM), derived from the patient’s own blood. The concentrated growth factors are injected into penile tissue to stimulate regeneration, improve cavernous blood flow, and promote neovascularization in erectile tissue.

The name is trademarked. Dr. Charles Runels registered the Priapus Shot® with the US Patent and Trademark Office on September 12, 2010. Only providers certified by the Cellular Medicine Association (CMA) may legally market the treatment as the “Priapus Shot®” or “P-Shot®.” Over 2,000 physicians in more than 50 countries have investigated the procedure through the CMA network, placing it firmly in the realm of recognized clinical inquiry rather than fringe treatment.

PRFM differs from standard PRP through an additional processing step that creates a fibrin matrix, potentially extending growth factor release over a longer window. Some NYC providers offer this as a premium variant.

One point deserves emphasis because it is routinely obscured: the P-Shot is not an FDA-approved structural penile enlargement procedure. It does not reliably produce measurable girth increases. This distinction is critical and underserved in competitor content.

The Step-by-Step Procedure: What to Expect at a NYC Appointment

A typical appointment follows a predictable sequence:

  1. Topical numbing cream is applied to the penis, usually 20 to 30 minutes before injection.
  2. A blood draw is taken from the arm, identical to a standard lab draw.
  3. Centrifugation isolates and concentrates the PRP or PRFM from the blood sample.
  4. Injection of concentrated growth factors into specific anatomical regions, primarily the corpus cavernosum and, in some protocols, the glans.

The total appointment runs approximately 15 to 30 minutes with little to no downtime. Because PRP is autologous (derived from the patient’s own blood), allergic reactions are extremely rare.

Post-procedure guidance typically includes: avoiding alcohol for three days prior; discontinuing blood thinners (aspirin, ibuprofen, fish oil) before treatment under physician guidance; refraining from sexual activity for 24 hours afterward; and avoiding strenuous exercise for 24 hours. Many providers also recommend a vacuum erection device protocol in the weeks following treatment to enhance tissue expansion and maximize regenerative results, a practical detail most NYC competitor pages omit entirely.

What Conditions Does the P-Shot Treat?

The primary indication is erectile dysfunction (ED), particularly mild-to-moderate vasculogenic ED. Secondary indications include Peyronie’s disease (penile curvature and fibrous plaque), decreased penile sensitivity, and sexual dysfunction following prostatectomy or radiation therapy, an underserved population with limited pharmaceutical options.

The scale of need is significant. According to the 2021 National Survey of Sexual Wellbeing, roughly 24.2% of US men meet diagnostic criteria for ED, yet only 7.7% have been formally diagnosed. Prevalence rises with age: 17.9% in men 18 to 24, 25.3% in men 45 to 54, and 33.9% in men 55 to 64. For busy, high-income professionals who want a no-downtime, non-pharmaceutical option that fits a demanding schedule, this represents a wide and largely unaddressed demographic.

The Clinical Evidence: What the Research Actually Shows in 2026

Most NYC provider pages make efficacy claims without a single citation. This section presents the actual data with honest commentary. It is worth stating upfront that Cleveland Clinic classifies the P-Shot as “experimental,” noting more research is needed to fully verify benefits. Acknowledging that reality builds trust with research-savvy readers rather than undermining the case.

The Landmark RCT: Poulios et al. (2021)

The strongest single piece of evidence is a double-blind, randomized, placebo-controlled trial, the gold standard in clinical research. Published in the Journal of Sexual Medicine, Poulios et al. studied 60 men with mild-to-moderate ED and found statistically significant improvements in IIEF-EF (International Index of Erectile Function, Erectile Function domain) scores at 1, 3, and 6 months post-treatment.

The honest limitation: n=60 is a relatively small sample, and results are most applicable to mild-to-moderate ED, not severe ED. Still, this remains the most-cited clinical evidence for the P-Shot’s efficacy and the study every informed NYC patient should know.

2025 Meta-Analyses: Broader Evidence Across Multiple RCTs

More recent evidence broadens the picture:

The honest takeaway: the evidence is promising and growing, but the field still lacks a single large-scale (n>200) multi-center RCT with standardized PRP protocols. That is the next evidentiary frontier.

Emerging Evidence: P-Shot for Peyronie’s Disease

Peyronie’s disease has limited non-surgical treatment options, which makes emerging PRP data meaningful for men in the stable phase who want to avoid surgery.

A single-center retrospective cohort study in MDPI Medicina (published January 2026) treated 36 men with chronic Peyronie’s disease using three weekly PRP injections. Mean penile curvature decreased from 30.5° to 24.2° (p<0.001) and plaque thickness declined significantly, with only mild transient adverse events. A 2025 AUA pilot study of 38 patients, published in the official journal of the American Urological Association, showed median curvature decreasing from 55° to 45° (p=0.02). An ongoing ClinicalTrials.gov trial reflects continued academic investment.

The honest framing: Peyronie’s data is earlier-stage than the ED evidence, and results vary by disease stage and plaque characteristics.

What the Evidence Does NOT Show: Honest Limitations

Balance is what separates a trustworthy source from a promotional page:

  • The P-Shot is not an FDA-approved structural enlargement procedure. Some men notice modest fullness from improved blood flow, but this is neither guaranteed nor the mechanism of action.
  • Much supporting evidence still comes from small trials with methodological limitations, including variable PRP preparation, differing injection techniques, and short follow-up periods.
  • Results are most consistent in mild-to-moderate ED; evidence for severe ED is limited.
  • The lack of a standardized PRP protocol makes direct comparison difficult and means outcomes can vary between providers.

Healthline (December 2025) fairly characterizes much of the supporting evidence as anecdotal or from small trials. Acknowledging that reality is precisely what makes the rest of the evidence credible.

Who Is an Ideal Candidate for the P-Shot in NYC?

The strongest candidates include:

  • Men with mild-to-moderate ED, especially those who have not responded well to PDE5 inhibitors (Viagra, Cialis) or who want to reduce pharmaceutical dependence.
  • Men with Peyronie’s disease in the stable phase seeking non-surgical curvature and plaque reduction.
  • Men with sexual dysfunction following prostate surgery or radiation.
  • Men seeking enhanced sensitivity and performance without medication.
  • Busy professionals who need a no-downtime, in-office procedure.

The common thread is realistic expectations. The P-Shot improves function and tissue quality; it is not a dramatic structural transformation.

Who Should NOT Get the P-Shot: Contraindications

Honest candidacy assessment is a trust signal. The P-Shot is not appropriate for men with:

  • Active blood disorders or platelet dysfunction.
  • Anticoagulant therapy that cannot be safely paused.
  • Active infections, particularly in the genital region.
  • Severe cardiovascular conditions where ED is primarily cardiac in origin (these men require cardiologic evaluation first).
  • Active prostate or penile cancer.
  • Compromised immune function.

Men with severe ED (IIEF-EF below 11) may see limited benefit based on current evidence. Men whose primary goal is measurable girth increase are looking at the wrong tool. HA filler, addressed below, is the appropriate solution for that goal.

P-Shot Results: Timeline, Duration, and Realistic Expectations

Growth factor activity peaks at 8 to 12 weeks post-injection, so patients should not judge outcomes at the 4-week mark, consistent with the 2025 meta-analysis finding no significant improvement at 4 weeks but significant improvement at 12 and 24 weeks. Results typically last 12 to 18 months, and many men choose annual repeat treatments.

What patients typically report: improved erectile rigidity, faster arousal response, enhanced sensitivity, and greater confidence. What they should not expect: guaranteed girth increase, instant results, or a cure for severe or psychogenic ED.

The vacuum pump protocol is relevant here as well. Using a vacuum erection device in the weeks after treatment is recommended by many providers to enhance tissue expansion. Combination protocols also improve outcomes; P-Shot plus low-intensity shockwave therapy (Li-SWT) is increasingly supported by evidence and offered by leading NYC providers.

P-Shot vs. Shockwave Therapy: Understanding the Synergy

Low-intensity shockwave therapy delivers acoustic waves to penile tissue, stimulating angiogenesis and nerve regeneration, a complementary but distinct mechanism from PRP. The 2025 meta-analysis specifically evaluated PRP alone and in combination with Li-SWT, finding significant IIEF improvements at 12 and 24 weeks. The University of Miami COCKTAIL-DM trial is actively investigating combined shockwave plus PRP for ED in diabetic men, providing academic validation of the approach.

For NYC patients, combination protocols represent the current evidence-based frontier for regenerative ED treatment. For men focused on aesthetic girth, however, the relevant conversation shifts entirely, which brings us to the most important distinction in this guide.

The Critical Distinction: P-Shot for Function vs. Filler for Form

This is the most underserved content gap in the NYC market. Most competitor pages blur the line.

  • P-Shot (PRP) targets erectile function, tissue regeneration, sensitivity, and Peyronie’s disease. The mechanism is biological and regenerative.
  • HA filler (filler phalloplasty) targets measurable aesthetic girth enhancement. The mechanism is volumetric, adding physical dimension beneath the penile skin.

A man asking “will the P-Shot make me bigger?” deserves an honest answer: possibly a modest improvement in fullness from better blood flow, but not a reliable, measurable girth increase. A man asking “how do I achieve a measurable increase in girth?” is asking about filler, not PRP.

For men whose goals include both improved function and measurable girth, a sequential protocol makes sense: the P-Shot as a functional foundation, followed by HA filler for aesthetic dimension. Mapping goals to treatments honestly is a trust-building differentiator no NYC competitor currently provides comprehensively.

Non-Surgical Girth Enhancement in NYC: When Filler Is the Right Tool

For men whose primary or secondary goal is measurable girth, HA-based dermal filler (filler phalloplasty) is the evidence-backed, non-surgical solution. Medical-grade, biocompatible hyaluronic acid filler is placed beneath the penile skin to enhance girth and volume, a structural rather than biological intervention.

The results profile includes immediate visible enhancement, an increase of up to 1 to 1.5 inches in girth, and results that look and feel natural in both flaccid and erect states while maintaining normal sensation and function. The procedure is non-surgical, requires no cutting or general anesthesia, and is completed in under one hour. Recovery is fast, with patients resuming normal activity within 10 days (compared to 40-plus days with other permanent fillers) and sexual activity within 7 to 10 days. Results deliver 80 to 90% permanent improvement in girth and volume, typically lasting 18 to 24 months.

The market reflects this shift. Google Trends data (2004 to 2024) shows “penis filler” searches climbing while traditional “penis enlargement” searches declined. The global male aesthetics market reached $5.9 to 6.61 billion in 2024 to 2025 and is projected to reach $11.17 to 11.8 billion by 2032 to 2034 (CAGR of approximately 7.2%). Male cosmetic procedures are up 325% since 2000, and 82% of male procedures in 2023 were non-surgical.

Filler Phalloplasty at Stoller Medical Group: The Evidence-Backed Girth Solution

Stoller Medical Group is the specialist practice for non-surgical girth enhancement in the NYC area, with more than 15,000 enlargement procedures performed, representing significant, specialized clinical expertise.

Dr. Roy B. Stoller is a board-certified physician with 25-plus years in aesthetic and restorative medicine and five years dedicated specifically to non-surgical male enhancement. The practice uses Belefil®, a hyaluronic acid-based, medical-grade, biocompatible filler designed for soft tissue augmentation, with transparent safety data.

The treatment philosophy is staged: multiple sessions rather than single dramatic procedures. This approach improves symmetry, reduces risk, and produces smoother, more natural outcomes. Procedures are performed with advanced training in male vascular and structural anatomy under hospital-grade sterility protocols.

Five locations serve the region, including Manhattan (515 Madison Avenue, Suite 1205), Long Island (Jericho), and Albany, plus Pennsylvania and Minnesota. Notably, the practice explicitly does not offer surgical penile lengthening due to higher associated risks, a decision that reflects prioritization of patient safety over revenue. Free consultations are available.

Understanding the Investment: Pricing for Filler Phalloplasty

Pricing for filler phalloplasty starts at $7,500 and increases depending on the patient’s desired results and anatomical goals. The structure is by syringe: most men begin with a minimum of 10 syringes, and the average first procedure involves 15 syringes.

Because the approach is staged, the investment is calibrated to the patient’s goals. A conservative first session can be followed by additional sessions for enhanced results. For the NYC professional, this is a specialized, physician-performed procedure backed by 15,000-plus cases of institutional experience, medical-grade materials, and hospital-grade protocols. A free consultation allows for personalized treatment planning and accurate cost estimation based on individual anatomy and goals.

For context, the P-Shot (PRP) is a separate service offered by other NYC providers at $1,500 to $3,000 per session and is not covered by insurance. The filler phalloplasty investment is similarly out-of-pocket but addresses a different set of goals.

P-Shot Pricing in NYC: What to Expect

NYC P-Shot pricing ranges from $1,500 to $3,000 per session, depending on provider credentials, clinic location, and whether the procedure is bundled with complementary services. The P-Shot is not covered by health insurance, as it is classified as elective and experimental, making the full cost out-of-pocket. Several NYC clinics offer financing options. Combination protocols command premium pricing but may offer enhanced outcomes based on the 2025 meta-analysis evidence.

Finding a Certified P-Shot Provider in New York City

Only providers certified by the Cellular Medicine Association (CMA) may legally market the treatment as the “Priapus Shot®” or “P-Shot®,” and patients should verify certification before proceeding. NYC (Manhattan and Brooklyn) is among the most accessible markets in the US for certified providers.

Key vetting criteria include: CMA certification, a board-certified physician performing the procedure, experience with male anatomy, and transparent discussion of both evidence and limitations. Red flags include any provider who claims the P-Shot guarantees girth increase, cannot cite clinical evidence when asked, or does not discuss contraindications. For men whose goals extend to girth enhancement, evaluating filler phalloplasty specialists is a separate process requiring a different skill set.

Frequently Asked Questions: P-Shot New York City

How long does the P-Shot last?

Results typically last 12 to 18 months, with growth factor activity peaking at 8 to 12 weeks. Many patients choose annual repeat treatments. The 4-week mark is too early to assess outcomes, consistent with meta-analysis data showing no significant improvement at 4 weeks but significant improvement at 12 and 24 weeks.

Can the P-Shot be combined with Viagra or Cialis?

Yes. The P-Shot and PDE5 inhibitors work through different mechanisms and are not contraindicated together. A 2022 pilot study specifically examined men with vascular ED unresponsive to PDE5 inhibitors and found significant IIEF-EF improvement after three PRP injections. Some men use medication during the 8 to 12 week regenerative window, then reassess with a physician.

P-Shot vs. shockwave therapy: which is better?

Neither is universally superior; they work through different mechanisms and are increasingly used together. Shockwave uses acoustic waves to stimulate angiogenesis, while PRP uses growth factors to stimulate regeneration. The 2025 meta-analysis evaluated both alone and in combination, and the University of Miami COCKTAIL-DM trial is actively investigating the combination for diabetic men. The right choice depends on individual diagnosis and provider recommendation.

Will the P-Shot increase size?

Not reliably or measurably. The P-Shot is not an FDA-approved structural enlargement procedure. Some men notice modest improvement in fullness from better blood flow, but this is not the mechanism of action. For measurable girth, HA filler (filler phalloplasty) is the evidence-backed solution.

How many P-Shot sessions are needed?

Most protocols involve 1 to 3 sessions. The 2022 pilot study used three injections 15 days apart and found significant improvement at one month. Annual maintenance is common. The optimal number depends on the indication, severity, and individual response.

Is the P-Shot safe? What are the side effects?

Common side effects are mild and transient: temporary swelling, bruising, soreness at the injection site, and possible mild discomfort during erections in the first 24 to 48 hours. Serious complications are rare. The 2023 systematic review noted a lack of adverse events across clinical studies, and because PRP is autologous, allergic reactions are extremely rare. Contraindications still apply.

What is the post-procedure protocol?

Patients should avoid alcohol three days prior, discontinue blood thinners under physician guidance, avoid sexual activity for 24 hours, and avoid strenuous exercise for 24 hours. Many providers recommend a vacuum erection device to enhance tissue expansion and maximize results. A follow-up is typically scheduled at 8 to 12 weeks to assess response.

Conclusion: Matching Goals to the Right Solution

The dual-track framework is the central point of this guide. The P-Shot (PRP) is a legitimate, evidence-supported option for men with mild-to-moderate ED, Peyronie’s disease, or post-surgical sexual dysfunction, with the 2021 Poulios RCT and 2025 meta-analyses providing meaningful clinical support. The limitations are real: the evidence is promising but not definitive, results build over weeks rather than days, and the P-Shot is not a structural enlargement procedure.

For men whose goals include measurable girth enhancement, filler phalloplasty is the evidence-backed, non-surgical solution: a different tool for a different goal. Both options are accessible in New York City with no downtime that would disrupt a demanding schedule. A man who has read this guide has the clinical literacy to ask the right questions at a consultation, which is exactly the purpose of evidence-first content. As the male aesthetics field continues to grow toward a projected $11.17 to 11.8 billion by 2032 to 2034, men who engage with it thoughtfully will make better decisions than those who rely on marketing copy alone.

Ready to Explore Your Options? Schedule a Free Consultation with Stoller Medical Group

For men ready to take the next step, a free, no-obligation consultation is the place to start. Stoller Medical Group brings 15,000-plus procedures performed, Dr. Roy B. Stoller’s 25-plus years of experience, a staged treatment approach, and a consistent focus on natural-looking results.

Consultations are discreet and confidential, a genuine priority for the NYC professional. The Manhattan office at 515 Madison Avenue, Suite 1205 offers local convenience, with additional New York locations in Long Island (Jericho) and Albany.

Filler phalloplasty starts at $7,500, with pricing increasing based on desired results and the number of syringes required. Most men begin with a minimum of 10 syringes, with the average first procedure involving 15 syringes. A free consultation provides personalized treatment planning and accurate cost estimation based on individual anatomy and goals. Every recommendation reflects a safety-first philosophy; the practice does not offer surgical procedures, which means guidance is aligned with the patient’s best interest. Results without surgery, without general anesthesia, and without weeks of recovery are within reach.

To schedule a free consultation at the Manhattan office or any of the five locations, visit the website or call to begin the conversation.